News & Press

AESTHETICS INDUSTRY VETERAN PAT ALTAVILLA JOINS SUNEVA MEDICAL AS VICE PRESIDENT OF MARKETING

San Diego, Calif. (October 10, 2016)—Suneva Medical, Inc., a privately-held aesthetics company, today announced the appointment of Pat Altavilla as vice president of marketing. With more than 30 years of experience in the aesthetics and medical fields, Altavilla will oversee all marketing aspects for the company, further fortifying the brand’s strong leadership position. “Pat’s experience …

AESTHETICS INDUSTRY VETERAN PAT ALTAVILLA JOINS SUNEVA MEDICAL AS VICE PRESIDENT OF MARKETING Read More »

SUNEVA APPOINTS PRESTON ROMM TO CHIEF EXECUTIVE OFFICER AND FORTIFIES BOARD OF DIRECTORS WITH INDUSTRY LEADERS

San Diego, CA (August 4, 2016)—Suneva Medical, Inc., a privately‐held aesthetics company, today announced the promotion of Preston Romm to president and chief executive officer, effective immediately. Romm, an industry veteran with more than 30 years of experience, recently joined the company as its chief operating officer and has been promoted to president and CEO …

SUNEVA APPOINTS PRESTON ROMM TO CHIEF EXECUTIVE OFFICER AND FORTIFIES BOARD OF DIRECTORS WITH INDUSTRY LEADERS Read More »

PRESTON ROMM JOINS SUNEVA MEDICAL AS CHIEF OPERATING OFFICER

Former Obagi Medical Products and Valeant Pharmaceuticals executive brings decades of experience to dynamic aesthetics company Appointment strengthens Suneva Medical’s executive team and accelerates its vision to become a leader in the cash-pay aesthetics market Romm will be responsible for the company’s sales, marketing and operations business functions San Diego, CA (June 16, 2016)—Suneva Medical, …

PRESTON ROMM JOINS SUNEVA MEDICAL AS CHIEF OPERATING OFFICER Read More »

SUNEVA MEDICAL CLOSES $25 MILLION FINANCING TO SUPPORT CONTINUED GROWTH OPPORTUNITIES

Financing includes $25 million equity investment from Essex Woodlands Growth equity firm’s healthcare expertise key to further elevate Suneva Medical as an innovative aesthetics leader San Diego, CA (June 14, 2016)—Suneva Medical, Inc., a privately-held and innovative aesthetics leader, today announced the closing of a $25 million investment by Essex Woodlands. This financing strengthens Suneva …

SUNEVA MEDICAL CLOSES $25 MILLION FINANCING TO SUPPORT CONTINUED GROWTH OPPORTUNITIES Read More »

SUNEVA MEDICAL RECOGNIZES JUNE ACNE AWARENESS MONTH AND REVEALS RESULTS OF NEW ACNE SCAR SURVEY

Survey results underscore the distressing realities of people living with acne scars Ninety-nine percent of respondents would have more confidence if their acne and acne scars were cleared up1 Celebrity dermatologist highlights Bellafill® as an effective acne scar treatment option San Diego, CA (June 7, 2016)—Suneva Medical, Inc., a privately-held aesthetics company, has revealed the …

SUNEVA MEDICAL RECOGNIZES JUNE ACNE AWARENESS MONTH AND REVEALS RESULTS OF NEW ACNE SCAR SURVEY Read More »

Important Safety Information

Bellafill®
Bellafill® is indicated for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. Patients who have had a positive reaction to the Bellafill® Skin Test, have a history of severe allergies, have known bovine collagen allergies, are allergic to lidocaine, have bleeding disorders or are prone to thick scar formation and/or excessive scarring should not receive Bellafill®. The safety of Bellafill® for use during pregnancy, breastfeeding, or in patients under 21 has not been established. You may experience temporary swelling, redness, pain, bruising, lumps/bumps, itching, and discoloration at the treatment site. These side effects are usually transient and typically resolve within 1–7 days. You may experience lumps/bumps/papules that may occur more than one month after injection and that may persist. Less common side effects include rash and itching more than 48 hours after treatment, persistent swelling or redness, lumps/bumps, acne, and increased sensitivity at treatment sites. Infrequently, granulomas may occur and may be treated by your licensed physician provider. Be sure to call your licensed provider immediately if you notice any unusual skin reactions around the treatment area. Based on the 5-year Post-Approval Study on nasolabial folds with 1,008 patients, long-term safety of Bellafill® for up to 5 years has been established.

PUREGRAFT
This product is certified as a medical device in the European Union under the Medical Device Directive 93/42/EEC by SGS CE0120, exclusively for the indication of autologous fat transfer. Other non-medical uses ascribed to this device such as aesthetic body contouring are not within the scope of CE certification, and users should be aware product performance and/or safety has not been evaluated by SGS for those purposes.

Suneva Medical HD PRP
REGULATORY STATUS: FDA-cleared 510(k) Class II medical device. Healeon HD PRP is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of peripheral blood at the patient point of care. The PRP is mixed with autograft and/orallograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK170136

For more safety information, please consult with your physician and the patient labeling that can be found by visiting our website www.bellafill.com.
Toll-free call (U.S. & Canada): 844-Bellafill (844-235-5234).
Local calls: 858-550-9999. International calls: ++ 858-550-9999.